Strongbridge Biopharma plc Profit Margin

The latest profit margin for SBBP is -115.66% as of June 2021. That compares with -205.02% in the prior-year period — up 43.6% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Strongbridge Biopharma plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, SBBP's profit margin moved from -205.02% to -115.66% — a 43.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Strongbridge Biopharma plc's valuation or profitability profile.

Against Healthcare companies, SBBP currently prints -115.66% for profit margin, while the sector average sits near 13.89%. That is roughly 932.5% below the sector mean. Large gaps often invite a closer look at Strongbridge Biopharma plc's growth, margins, and balance sheet.

Profit Margin shows how effectively Strongbridge Biopharma plc converts resources into returns. At -115.66%, SBBP may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -205.02% in the prior-year period — up 43.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SBBP's profit margin (-115.66%), review year-over-year change from -205.02%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.